GlassScriptPhysician profile
Jonathan F Thomas
NPI 1043210149
$4,847.17
in general payments reported to CMS, 2019-2025
50 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $678 · 2021: $345 · 2022: $839 · 2023: $573 · 2024: $592 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $954.48 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $762.36 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $461.90 | 2019-2025 | Tremfya |
| Abbvie INC. | $279.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $256.39 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $241.95 | 2019-2025 | |
| Pfizer INC. | $195.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $176.10 | 2020-2025 | Benlysta |
| Genzyme Corporation | $165.40 | 2020-2025 | |
| Lilly USA, LLC | $132.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $94.37 | 2022-2024 | Saphnelo |
| Seagen INC. | $89.01 | 2020-2022 | |
| Incyte Corporation | $88.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.11 | 2020-2023 | |
| Celgene Corporation | $56.23 | 2019 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.